scFv-Transferrin Fusion Protein for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies lack the ability to effectively cross biological barriers such as the blood-brain barrier or enter cancerous cells due to their molecular size and the unnecessary interaction with Fc receptors, limiting their therapeutic efficacy and application.
Innovation Solution
Development of a single-chain variable fragment (scFv) antibody fused with the N-methyl lobe of transferrin protein, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis, with enzymatically or pH-sensitive linkers for controlled release within target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used, then effector functions and half-life are enhanced, but the ability to cross biological barriers is reduced
Solution Approach 1:
The patent divides the antibody into functional segments: the scFv fragment (containing variable regions for antigen binding) is separated from the Fc region (containing effector functions). This segmentation allows the scFv to be optimized for crossing biological barriers while the Fc region can be separately optimized for effector functions, resolving the contradiction between barrier penetration and effector capability.
Solution Approach 2:
The patent introduces transferrin as an intermediary carrier protein that facilitates the transport of scFv across biological barriers. The scFv binds to transferrin, which then mediates its delivery across the blood-brain barrier and other biological membranes through transcytosis, enabling the small fragment to overcome size-related barriers without requiring full antibody effector functions.
2Ease of operation
If an scFv is used, then the ability to cross biological barriers is improved, but effector functions and half-life are reduced
Solution Approach 1:
The antibody is segmented into scFv (for barrier crossing) and Fc region (for effector functions), allowing each component to be optimized independently for its specific function rather than compromising one for the other.
Solution Approach 2:
The patent creates a multi-functional system where scFv provides both barrier crossing capability and antigen binding, while the Fc region provides effector functions. The combination of these separated components achieves multiple functions that neither fragment could achieve alone, resolving the trade-off between barrier penetration and effector capability.
3Productivity
If a fusion protein with transferrin is created, then cellular uptake is enhanced, but the complexity of the molecule is increased
Solution Approach 1:
The patent merges the scFv fragment with the transferrin carrier protein into a single fusion protein construct. This combining approach enhances cellular uptake by utilizing transferrin's established endocytic pathways while maintaining a relatively simple molecular structure compared to full antibody-Fc modifications, achieving improved productivity without excessive complexity.
Solution Approach 2:
Transferrin serves as an intermediary carrier that simplifies the delivery mechanism. Instead of designing complex delivery systems, the patent leverages transferrin's natural role in cellular iron transport and endocytosis as a mediator to facilitate scFv uptake, reducing the complexity of the overall delivery system while enhancing cellular uptake efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the delivery of therapeutic antibodies across biological barriers, improving efficacy by increasing cellular uptake and reducing off-target effects through targeted and controlled release of the scFv.
Implementation Method 1
utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake and transcytosis
Implementation Method 2
enzymatically or pH-sensitive linkers for controlled release within target cells
Implementation Method 3
enzymatically or pH-sensitive linkers for controlled release within target cells
Data Source
AI summary
The efficacy and indication of zagotenemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.